COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
To create more flexible conditions for COVID-19 vaccine distribution, the Food and Drug Administration (FDA) announced undiluted frozen vials of the Pfizer-BioNTech vaccine
Recent advisories from the Centers for Disease Control and Prevention (CDC) cover a wide range of COVID-19 topics, including testing health care personnel, mitigating staffing shortages and return-to-work criteria.
The Centers for Disease Control and Prevention (CDC) updated its infection prevention guidance for health care personnel on Feb. 10.
Last week, the Department of Health and Human Services (HHS) expanded the categories of clinicians authorized to prescribe, dispense and administer COVID-19 vaccines.
The Food and Drug Administration (FDA) issued updated guidance this month related to its emergency use authorizations for N95 respirator decontamination systems. The authorization now limits respirator reuse to no more than four times.
According to the Centers for Disease Control and Prevention (CDC), a more highly transmissible variant of SARS-CoV-2, B.1.1.7, has been detected in 12 U.S. states, putting the country at risk for a rise in COVID-19 cases, hospitalizations and deaths.
To reduce the risk of false negative results for COVID-19, the FDA issued guidance this week for safely using the Curative SARS-CoV-2 test.
Anaphylaxis, a life-threatening allergic reaction, occurred in 11.1 cases per million doses of Pfizer-BioNTech COVID-19 vaccine administered in the United States during the week of Dec. 14, 2020.
The Department of Health and Human Services (HHS) posted two requests for information last week.